| Engineering an artificial T‐cell stimulating matrix for immunotherapy JW Hickey, Y Dong, JW Chung, SF Salathe, HC Pruitt, X Li, C Chang, ... Advanced Materials 31 (23), 1807359, 2019 | 145 | 2019 |
| Hydrogel network dynamics regulate vascular morphogenesis Z Wei, R Schnellmann, HC Pruitt, S Gerecht Cell stem cell 27 (5), 798-812. e6, 2020 | 118 | 2020 |
| microRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancer JW Rostas, HC Pruitt, BJ Metge, A Mitra, SK Bailey, S Bae, KP Singh, ... Molecular cancer 13, 1-11, 2014 | 88 | 2014 |
| Collagen fiber structure guides 3D motility of cytotoxic T lymphocytes HC Pruitt, D Lewis, M Ciccaglione, S Connor, Q Smith, JW Hickey, ... Matrix Biology 85, 147-159, 2020 | 75 | 2020 |
| IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cells EM McCoy, H Hong, HC Pruitt, X Feng BMC cancer 13, 1-11, 2013 | 72 | 2013 |
| Hypoxia and matrix viscoelasticity sequentially regulate endothelial progenitor cluster-based vasculogenesis MR Blatchley, F Hall, S Wang, HC Pruitt, S Gerecht Science advances 5 (3), eaau7518, 2019 | 62 | 2019 |
| Methods to evaluate cell growth, viability, and response to treatment in a tissue engineered breast cancer model KF Goliwas, JR Richter, HC Pruitt, LM Araysi, NR Anderson, RS Samant, ... Scientific reports 7 (1), 14167, 2017 | 40 | 2017 |
| A feedback loop between hypoxia and matrix stress relaxation increases oxygen-axis migration and metastasis in sarcoma DM Lewis, H Pruitt, N Jain, M Ciccaglione, JM McCaffery, Z Xia, K Weber, ... Cancer research 79 (8), 1981-1995, 2019 | 30 | 2019 |
| Roles of N‐Myc and STAT interactor in cancer: From initiation to dissemination HC Pruitt, DJ Devine, RS Samant International journal of cancer 139 (3), 491-500, 2016 | 25 | 2016 |
| Hypoxia re-programs 2′-O-Me modifications on ribosomal RNA BJ Metge, SC Kammerud, HC Pruitt, LA Shevde, RS Samant Iscience 24 (1), 2021 | 23 | 2021 |
| Disruption of STAT5A and NMI signaling axis leads to ISG20-driven metastatic mammary tumors HAM Alsheikh, BJ Metge, HC Pruitt, SC Kammerud, D Chen, S Wei, ... Oncogenesis 10 (6), 45, 2021 | 20 | 2021 |
| Developing cures: targeting ontogenesis in cancer VTG Lin, HC Pruitt, RS Samant, LA Shevde Trends in cancer 3 (2), 126-136, 2017 | 14 | 2017 |
| Nanoparticle-based modulation of CD4+ T cell effector and helper functions enhances adoptive immunotherapy A Isser, AB Silver, HC Pruitt, M Mass, EH Elias, G Aihara, SS Kang, ... Nature communications 13 (1), 6086, 2022 | 13 | 2022 |
| Collagen VI deposition mediates stromal T cell trapping through inhibition of T cell motility in the prostate tumor microenvironment HC Pruitt, Y Guan, H Liu, AE Carey, WN Brennen, J Lu, C Joshu, ... Matrix Biology 121, 90-104, 2023 | 12 | 2023 |
| Conditional knockout of N-Myc and STAT interactor disrupts normal mammary development and enhances metastatic ability of mammary tumors HC Pruitt, BJ Metge, SE Weeks, D Chen, S Wei, RA Kesterson, ... Oncogene 37 (12), 1610-1623, 2018 | 12 | 2018 |
| BH3 mimetics suppress CXCL12 expression in human malignant peripheral nerve sheath tumor cells CD Graham, N Kaza, HC Pruitt, LM Gibson, BJ Klocke, LA Shevde, ... Oncotarget 8 (5), 8670, 2016 | 6 | 2016 |
| Immunotherapy: Engineering an Artificial T‐Cell Stimulating Matrix for Immunotherapy (Adv. Mater. 23/2019) JW Hickey, Y Dong, JW Chung, SF Salathe, HC Pruitt, X Li, C Chang, ... Advanced Materials 31 (23), 1970162, 2019 | 4 | 2019 |
| Oncogene-induced matrix reorganization controls CD8+ T cell function in the soft-tissue sarcoma microenvironment AM Fuller, HC Pruitt, Y Liu, VM Irizarry-Negron, H Pan, H Song, A DeVine, ... The Journal of Clinical Investigation, 2024 | 3 | 2024 |
| Tumor Ecosystems and Immune Microenvironment I Abstracts AM Fuller, HC Pruitt, H Song, Y Liu, A Devine, RS Katti, S Devalaraja, ... CLINICAL CANCER RESEARCH 28 (18), 1-1, 2022 | | 2022 |
| Abstract PR001: Oncogene-induced matrix reorganization controls CD8+ T cell immunity in the UPS microenvironment AM Fuller, HC Pruitt, H Song, Y Liu, A Devine, RS Katti, S Devalaraja, ... Clinical Cancer Research 28 (18_Supplement), PR001-PR001, 2022 | | 2022 |
